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Abstract
Background: Fibrinogen concentrates and cryoprecipitate are currently used
for fibrinogen supplementation in bleeding patients with dysfibrinogenemia.
Both products provide an abundant source of fibrinogen but take greater than
10 min to prepare for administration. Fibrinogen concentrates lack coagulation
factors (i.e., factor VIII [FVIII], factor XIII [FXIII], von Willebrand factor
[VWF]) important for robust hemostatic function. Cryoprecipitate products
contain these factors but have short shelf lives (<6 h). Pathogen reduction
(PR) of cryoprecipitate would provide a shelf-stable immediately available
adjunct containing factors important for rescuing hemostatic dysfunction.
Study Design and Methods: Hemostatic adjunct study products were
psoralen-treated PR-cryoprecipitated fibrinogen complex (PR-Cryo FC),
cryoprecipitate (Cryo), and fibrinogen concentrates (FibCon). PR-Cryo FC and
Cryo were stored for 10 days at 20–24°C. Adjuncts were added to coagulopathies
(dilutional, 3:7 whole blood [WB]:normal saline; or lytic, WB + 75 ng/ml tissue
plasminogen activator), and hemostatic function was assessed by rotational
thromboelastometry and thrombin generation.
Results: PR of cryoprecipitate did not reduce levels of FVIII, FXIII, or VWF.
PR-Cryo FC rescued dilutional coagulopathy similarly to Cryo, while generating
significantly more thrombin than FibCon, which also rescued dilutional
coagulopathy. Storage out to 10 days at 20–24°C did not diminish the hemostatic
function of PR-Cryo FC.
Discussion: PR-Cryo FC provides similar and/or improved hemostatic rescue
compared to FibCon in dilutional coagulopathies, and this rescue ability is stable over 10 days of storage. In hemorrhaging patients, where every minute
delay is associated with a 5% increase in mortality, the immediate availability
of PR-Cryo FC has the potential to improve outcomes.
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1 | INTRODUCTION
Mortality at 28 days is high in patients with severe traumatic hemorrhage, ranging between 20% and 24% in
adults1,2 and 36% and 50% in children.3,4 Impaired fibrinogen function is highly associated with mortality in these
patients with traumatic bleeding,5,6 and transfusion
of
fibrinogen-containing
products
may improve
7–10
Currently, there are two sources of exogeoutcomes.
nous fibrinogen used during resuscitation: fibrinogen concentrates and cryoprecipitate. To date, there are no
published clinical studies comparing the impact of fibrinogen concentrates versus cryoprecipitate use on clinical outcomes in trauma patients with severe bleeding, resulting in
a lack of consensus regarding which of these two products
are optimal for severe traumatic bleeding.11 In vitro studies
suggest that cryoprecipitate attenuates hyperfibrinolysis
more effectively than fibrinogen concentrates.12 This is relevant to trauma patients as hyperfibrinolysis is a source of
coagulopathy and a strong predictor of increased mortality.13 Lastly, other studies have revealed that factor VIII
(FVIII), factor XIII (FXIII), and von Willebrand factor
(VWF) deficiencies are associated with worse outcomes in
traumatic bleeding patients suggesting that cryoprecipitate
may be an optimal product compared to fibrinogen concentrates in this population14–18 and in other severely bleeding
populations, such as cardiac and obstetric bleeding.19
Fibrinogen concentrates and cryoprecipitate each have
advantages and disadvantages. Fibrinogen concentrates
provide consistent amounts of fibrinogen between batches,
are lyophilized allowing for long-term storage, and remove
the risk of transfusion transmitted infections (TTIs).20
However, fibrinogen concentrates take approximately
15 min to reconstitute21 and are very expensive (current
average price: $734/g of fibrinogen in United States).22 In
contrast, cryoprecipitate contains additional coagulation
factors (fibrinogen [FGN], FVIII, FXIII, and VWF) important for hemostasis23 and is 3–4 times cheaper than fibrinogen concentrates when compared with per gram of
fibrinogen.22,24 Disadvantages include increased batch-tobatch variation in fibrinogen content, a very small
increased risk of TTIs due to pooling, and logistical issues:
cryoprecipitate is frozen and requires 20 min to thaw and
expires 6 h post-thaw, increasing waste. An immediately
available (i.e., no reconstitution or thaw time) fibrinogen
supplement with an extended shelf life could potentially
improve outcomes in traumatically bleeding patients.25

Recent advances in the field of blood product safety
have resulted in the implementation of pathogen reduction (PR) technology for multiple blood products as PR
prevents replication of bacteria, viruses, and parasites
associated with TTIs.26 Multiple PR technologies exist
globally for use on plasma products and can be adapted
for use with cryoprecipitate products to generate a
pathogen-reduced cryoprecipitate product. This would
have the potential to extend cryoprecipitate product shelf
life without the risk of pathogen growth over time, thereby
improving product safety profiles. Very recently, the Food
and Drug Administration (FDA) approved a pathogenreduced cryoprecipitated fibrinogen complex product for
use out to 5 days post-thaw,27 which has been shown to
rescue in vitro derived dilutional coagulopathies.28,29 However, questions remain regarding the hemostatic efficacy
of pathogen-reduced cryoprecipitate products, such as the
maximum length of storage at which the product maintains functionality, the ability of the product to improve
hyperfibrinolysis, and how long-term-stored pathogenreduced cryoprecipitate products perform compared to
current clinically used fibrinogen concentrates and
cryoprecipitate.
Herein, we induced two distinct coagulopathies
in vitro and resuscitated with hemostatic adjuncts (pathogen-reduced cryoprecipitate product, cryoprecipitate, or
fibrinogen concentrate) then measured hemostatic rescue
to
determine
whether
the
pathogen-reduced
cryoprecipitate product was an effective and comparable
adjunct. We induced a dilutional coagulopathy to mimic
the iatrogenic effects of resuscitation with crystalloids,
and a lytic coagulopathy (addition of tissue plasminogen
activator [tPA]) to test the hypothesis that increased
FXIII in cryoprecipitate-based products would stabilize
fibrin crosslinking and reduce fibrinolysis. We also tested
whether storing pathogen-reduced cryoprecipitate product out to 10 days would affect its hemostatic efficacy
compared to fibrinogen concentrate and cryoprecipitate.

2 | MATERIALS AND METHODS
2.1 | Whole blood sources and
coagulopathic model induction
Healthy donors of any ABO blood type were consented
and enrolled according to Washington University in
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St. Louis Institutional Review Board approval
#201901135, using inclusion/exclusion criteria provided
in Supplemental Methods. Whole blood (WB, 45 ml) was
collected via venipuncture into sodium citrate vacutainers, and basic demographic data were collected
(Table S1). Coagulopathic models were induced, and
hemostatic function was measured using rotational
thromboelastometry (ROTEM) and thrombin generation
(Figure S1(A), Table S2). To create the dilutional
coagulopathic model (dWB), WB was diluted in normal
saline in a 3:7 ratio, resulting in a doubling of clot formation time (CFT) and a 50% reduction in the maximum
clot firmness (MCF) after extrinsic activation (ExTEM).
To induce the lytic coagulopathy model (lyWB), WB was
dosed with tPA (75 ng/ml30), resulting in 10%–15% lysis
after extrinsic activation. Both models recapitulate
coagulopathies that have been demonstrated to be clinically relevant or associated with worse outcomes in
patients with trauma-induced coagulopathy.31

1945

50 ml of sterile water for injection according to the manufacturer's protocol to obtain a 0.02 g/ml solution. The
concentration was adjusted with normal saline to achieve
a final fibrinogen concentration equal to the average
fibrinogen concentration in all six Cryo units tested upon
thaw (791.5 mg/dl, described in Supplemental Materials).

2.3 | Rescue of coagulopathy
Study products were combined with dWB or lyWB in a
1:5 fashion (PR-Cryo FC:dWB; Cryo:dWB; FibCon:dWB;
PR-Cryo FC:lyWB; Cryo:lyWB; FibCon:lyWB), resulting
in a study product fibrinogen dose of 158.3 mg/dl
(roughly the equivalent of a 4g FC dose in an 80kg adult).
Study product:coagulopathy mixtures were assessed by
traditional hemostatic assays (Figure S1(A)). Mixtures
were made, and assays performed on days 0, 2, 5, 7, and
10 of storage after thawing for cryoprecipitate-based
products and within 6 h after reconstitution for FibCon.

2.2 | Hemostatic adjuncts
2.4 | Traditional hemostatic assays
Hemostatic adjunct study products (n = 6 each group)
were (i) psoralen-treated PR-Cryoprecipitated Fibrinogen
Complex
(“PR-Cryo
FC”),
(ii)
Cryoprecipitate
Antihemophilic Factor (“Cryo”), and (iii) fibrinogen concentrates (“FibCon”). PR-Cryo FC is produced through
cryoprecipitation of proteins from plasma that has been
treated with the INTERCEPT® Blood System for plasma.
After treatment, the plasma is transferred to the storage
container of the INTERCEPT set. The plasma storage
containers containing INTERCEPT processed plasma are
then sterile connected to the FIBRICEPT processing container (FPC), the proprietary container designed for the
manufacturing of PR-Cryo FC. The plasma is transferred
to the FPC, and the bundle is frozen at −18°C or colder
and held for up to 30 days. The plasma is then thawed
gradually at 1–6°C and then centrifuged using a hard
spin at 1–6°C, resulting in the separation into a
cryoprecipitated pellet (PR-Cryo FC) and plasma
cryoprecipitate-reduced (PRPCR) supernatant. The
PRPCR is transferred into two of the three final storage
containers, with 60–100 ml of PRPCR supernatant
remaining in the FPC for resuspension of PR-Cryo
FC. The resuspended PR-Cryo FC is transferred to the
remaining storage container and was pooled prior to
freezing. The PR-Cryo FC was stored frozen at −18°C or
colder. PR-Cryo FC and Cryo products were manufactured and provided by Cerus Corporation, stored at
−20°C until thaw, and post-thaw, they were stored out to
10 days at 20–24°C. One gram of FibCon (RiaSTAP®,
CSL-Behring) was reconstituted on the day of assay in

Study product:coagulopathy mixtures were assayed using
ROTEM (ROTEM delta Analyzer; TEM International
GmbH,
Munich,
Germany).
ExTEM
reagent
(Instrumentation Laboratories World Wide [ILWW],
Durham, NC, United States) was used for activation, and
StarTEM reagent (ILWW) was used for recalcification.
Assays were run for 60 min according to the manufacturer's suggested protocol. Clotting time (CT, seconds),
CFT (seconds), alpha angle (α, °), MCF (millimeters
[mm]), and lysis at 60 min (LY60, %) were recorded.
Platelet-rich plasma (PRP) was generated from study
product coagulopathy mixtures (160 g, 10 min, 22°C) and
used in thrombin generation assays. In brief, 80 μl of PRP
was added to 20 μl of reconstituted PRP reagent (Tissue
Factor (TF), 5 pM) and mixed with FluCa buffer and substrate, and thrombin generation was measured (absorbance at 460 nm, every 20 s for 60 min) using a calibrated
automated thrombinoscope (Diagnostica Stago Inc.,
Maastricht, The Netherlands) according to the manufacturer's protocol. Endogenous thrombin potential (ETP,
nM*min), lag time (time to initial thrombin generation,
min), maximal thrombin generation (Peak, nM), and time
to peak (Time to Peak, min) were reported.
Platelet-poor plasma (PPP) was generated from study
product:coagulopathy mixtures (1600 g, 10 min, 22°C;
then 2500 g, 10 min, 22°C) and frozen (−80°C) until
batched analysis of coagulation factors (FGN, FVIII, FXIII,
and VWF) using the Stago Compact Max coagulation analyzer (Diagnostica Stago, Parsippany, NJ, United States).
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Variable

FibCon

Cryo

PR-Cryo FC

p values

FGN

730.5 (564.5–796.8)

758.5 (636.0–960.0)

760.5 (687.5–797.5)

ns,ns,ns

FVIII

10.00 (8.00–10.00)

229.5 (210.0–324.3)

175.5 (134.5–192.8)

***,ns,ns

FXIII

92.00 (51.75–109.8)

284.5 (163.8–303.3)

366.5 (42.50–377.3)

ns,ns,ns

VWF

154.5 (139.0–178.8)

404.5 (331.8–616.3)

491.5 (412.0–609.0)

*,**,ns

T A B L E 1 Pathogen reduction of
cryoprecipitate products does not
decrease factor levels

Note: Fibrinogen (FGN), factor VIII (FVIII), factor XIII (FXIII), and von Willebrand factor (VWF) levels in
thawed (PR-Cryo FC and Cryo) or reconstituted (FibCon) products. Data are reported as median
(interquartile range [IQR; Quartile 1–Quartile 3]) and compared by Kruskal–Wallis analysis with Dunn's
post hoc test to determine p values (n = 6 per treatment group). p values (ns p > .05; *p < .05; **p < .01; and
***
p < .001) are reported in the order of these comparisons: FibCon to Cryo, FibCon to PR-Cryo FC, and
Cryo to PR-Cryo FC.
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F I G U R E 1 PR-Cryo FC and Cryo have improved thrombin generation compared to FibCon during hemostatic rescue of induced
dilutional coagulopathy. Hemostatic adjuncts (fibrinogen concentrates, FibCon; cryoprecipitate, Cryo; and psoralen-treated PRcryoprecipitated fibrinogen complex, PR-Cryo FC) were added to the induced dilutional coagulopathy (dWB), and the following
measurements were made: (A) clotting time (CT, seconds), (B) clot formation time (CFT, seconds), (C) maximal clot firmness (MCF, mm),
(D) percent lysis at 60 min (LY60, %), (E) endogenous thrombin potential (ETP, nM*min), (F) lag time (min), (G) peak (nM), (H) time to
peak (ttPeak, min), (I) fibrinogen (FGN, mg/dl), (J) factor VIII (FVIII, %), (K) factor XIII (FXIII, %), and (L) von Willebrand factor (VWF).
Data are represented as individual points and with median ± interquartile range (IQR), and Kruskal–Wallis analysis between groups
determine p values (n = 6 per treatment group); ns, p > .05; *, p < .05; and **, p < .01. Significance values directly above each column are
comparing the given column to PR-cryo FC, whereas bars above given columns indicate the comparison being made. Dotted lines bound the
whole blood reference ranges
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At the time of assay, PPP was thawed at 37°C for 10 min,
then assayed for FGN (STA FIBRINOGEN 5), FVIII (STA
Deficient VIII), FXIII (K-assay FXIII), and VWF (STA
LIATEST VWF:AG). All additional Stago reagents were
used as indicated by package inserts in the associated tests.

2.5 | Statistical analyses
Data were analyzed using GraphPad Prism software (version 9.0.0 for Windows; GraphPad Software, La Jolla, CA,
United States, www.graphpad.com) and R 3.4.3
(2017-11-30, Vienna, Austria). Data are reported as
median (interquartile range [IQR]) and represented as
individual data points, with a bar at the median value and
error bars denoting IQR. Comparison between adjuncts
used to rescue coagulopathies was performed by one-way
analysis of variance (ANOVA, Kruskal–Wallis test), and if
the p value was significant (p < .05), then Dunn's multiple
comparison test was performed to compare adjuncts to
one another. Comparison of a given variable over the
course of storage in a single study product group was performed by one-way ANOVA (Kruskal–Wallis test), and if
the p value was significant (p < .05), then Dunn's multiple
comparison test was performed to compare values on different storage days to one another. Mann–Whitney tests
were used to compare predefined storage days of one study
product to predefined storage days of another adjunct
(e.g., PR-Cryo FC Day 10 to FibCon Day 0).

3 | R E SUL T S
3.1 | Pathogen reduction does not alter
coagulation factor levels in cryoprecipitate
PR-Cryo FC had similar levels of FGN, FVIII, FXIII, and
VWF compared to Cryo (Table 1), suggesting that PR
treatment does not alter the baseline levels of these
important coagulation factors. Notably, while FGN levels
were similar across all three hemostatic adjuncts
(Table 1), FibCon contained at least a third of the FVIII,
FXIII, and VWF compared to PR-Cryo FC (Table 1).

3.2 | Pathogen-reduced cryoprecipitate
provides similar hemostatic function to
cryoprecipitate in both dilutional and lytic
coagulopathies
At Day 0, PR-Cryo FC, Cryo, and FibCon all rescued
dWB to the same degree, as the CTs (Figure 1(A)), CFTs
(Figure 1(B)), MCF (Figure 1(C)), and lysis (LY60,

1947

Figure 1(D)) were not significant from each other. ETP
was similar in both PR-Cryo FC:dWB and Cryo:dWB
(Figure 1(E)). However, ETP was reduced by 49% when
FibCon was used to resuscitate dWB compared to PRCryo FC (Figure 1(E)). Lag time was similar no matter
the adjunct used (Figure 1(F)), whereas FibCon:dWB
resulted in peak thrombin levels almost a third of that
generated in PR-Cryo FC:dWB or Cryo:dWB (Figure 1
(G)), and the time to peak thrombin generation was significantly delayed (2-fold) in FibCon:dWB compared to
PR-Cryo FC:dWB or Cryo:dWB (Figure 1(H)). FGN
levels were slightly yet significantly elevated in FibCon:
dWB compared to PR-Cryo FC:dWB (Figure 1(I)). While
not statistically different, there was a 3-fold reduction in
FVIII levels in FibCon:dWB compared to PR-Cryo FC:
dWB (Figure 1(J)). Importantly, FibCon use failed to
bring FVIII levels back to normal healthy WB levels,
whereas PR-Cryo FC and Cryo both resuscitated dWB
back to healthy WB levels. FibCon:dWB also resulted in
decreased FXIII (Figure 1(K)) and VWF (Figure 1(L))
levels when compared to PR-Cryo FC:dWB or
Cryo:dWB.
At Day 0, PR-Cryo FC, Cryo, and FibCon all rescued
lytic coagulopathy in a comparable manner (Figure 2).
CT, CFT, MCF, and LY60 (Figure 2(A)–(D)) of study
product:lyWB mixtures were similar between study
groups. ETP (Figure 2(E)) and lag time (Figure 2(F))
were approximately the same in PR-Cryo FC:lyWB,
Cryo:lyWB, and FibCon:lyWB. While peak thrombin
generation and time to peak thrombin generation in
resuscitated lyWB were similar to the dWB profile, these
trends of reduced peak and delayed time to peak in
FibCon:lyWB were not significant from PR-Cryo FC:
lyWB (Figure 2(G),(H)). There was again an increase in
FGN levels in FibCon:lyWB compared to PR-Cryo FC:
lyWB (Figure 2(I)), although not significant. Similar to
the dWB model, there was a 2-fold reduction in FVIII in
FibCon:lyWB compared with PR-Cryo FC:lyWB,
although this was not significant (Figure 2(J)). FXIII
levels were reduced in FibCon:lyWB compared with PRCryo FC:lyWB, but FXIII levels in both treatment
groups were well above normal healthy WB levels
(Figure 2(K)). Lastly, VWF levels were increased by
2-fold in PR-Cryo FC:lyWB compared to FibCon:lyWB
(Figure 2(L)).

3.3 | Long-term storage of pathogenreduced cryoprecipitate does not decrease
hemostatic function
Storage of PR-Cryo FC at 20–24°C out to 10 days had
no effect on the ability of PR-Cryo FC to serve as an
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F I G U R E 2 PR-Cryo FC and Cryo provide similar hemostatic rescue of induced lytic coagulopathy compared to FibCon. Hemostatic
adjuncts (fibrinogen concentrates, FibCon; cryoprecipitate, Cryo; and psoralen-treated PR-cryoprecipitated fibrinogen complex, PR-cryo FC)
were added to induced lytic coagulopathy (lyWB), and the following measurements were made: (A) clotting time (CT, seconds), (B) clot
formation time (CFT, seconds), (C) maximal clot firmness (MCF, mm), (D) percent lysis at 60 min (LY60, %), (E) endogenous thrombin
potential (ETP, nM*min), (F) lag time (min), (G) peak (nM), (H) time to peak (ttPeak, min), (I) fibrinogen (FGN, mg/dl), (J) factor VIII
(FVIII, %), (K) factor XIII (FXIII, %), and (L) von Willebrand factor (VWF). Data are represented as individual points and with
median ± interquartile range (IQR), and Kruskal–Wallis analysis between groups determine p values (n = 6 per treatment group); ns,
p > .05; *, p < .05; **, p < .01; and ***, p < .001. Significance values directly above each column are comparing the given column to PR-Cryo
FC, whereas bars above given columns indicate the comparison being made. Dotted lines bound the whole blood reference ranges

effective hemostatic adjunct for both dilutional and
lytic coagulopathies (Figure 3). While there was a
consistent 30% reduction in CFT when stored (D2-10)
PR-Cryo FC rather than fresh (D0) PR-Cryo FC was
used to rescue dWB, the reduced CFT was still greater
than that of healthy WB (Figure 3(B)). In addition,
rescue of lyWB with stored PR-Cryo FC led to
increases in FGN, FXIII, and VWF that were beyond
the upper limit of the reference ranges (Figure 3(F),
(H), (I)).

3.4 | Stored pathogen-reduced
cryoprecipitate improves clotting initiation
and thrombin generation in dilutional
coagulopathy compared to fibrinogen
concentrates
Lastly, we compared hemostatic function between
coagulopathies rescued by D5 or D10 PR-Cryo FC versus
either D0 Cryo or D0 FibCon (Table 2). FVIII, FXIII,
VWF, thrombin generation (ETP, peak, and time to
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CT (sec)

A 150

1949

15
10
5

600
400
200
0

J 200

K 300

L 350

FXIII (%)

150
100
50
0

0
2
5
7
10
Storage Duration (days)

VWF (%)

0

FVIII (%)

0

200
100
0

0
2
5
7
10
Storage Duration (days)

300
250
200
150
100
50
0

0
2
5
7
10
Storage Duration (days)

dWB + PR-Cryo FC
lyWB + PR-Cryo FC
F I G U R E 3 PR-Cryo FC stored out to 10 days does not significantly affect hemostatic rescue of dilutional or lytic coagulopathies. PRCryo FC stored out to 10 days was added to dilutional (dWB) or lytic (lyWB) coagulopathies, and the following measurements were made:
(A) clotting time (CT, seconds), (B) clot formation time (CFT, seconds), (C) maximal clot firmness (MCF, mm), (D) percent lysis at 60 min
(LY60, %), (E) endogenous thrombin potential (ETP, nM*min), (F) fibrinogen (FGN, mg/dl), (G) factor VIII (FVIII, %), (H) factor XIII
(FXIII, %), and (I) von Willebrand factor (VWF). Data are represented as summary data points and with median ± interquartile range (IQR);
n = 6 per group

peak), and CT were all significantly improved in D10 PRCryo FC:dWB when compared to FibCon:dWB. CT and
thrombin generation parameters (lag time and time to
peak) were elongated, and CFT and MCF reduced in D10
PR-Cryo FC:dWB compared to D0 Cryo:dWB. There were

no significant differences in functional hemostatic
parameters between D10 PR-Cryo FC:lyWB and D0
FibCon:lyWB, while factor levels in FibCon:lyWB
remained significantly lower than the levels in both D5
and D10 PR-Cryo FC:lyWB. There was little difference
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TABLE 2

Comparison of D5 or D10 PR-Cryo FC to D0 Cryo or D0 FibCon in all assays

Variable

FibCon D0

Cryo D0

PR-Cryo FC D5

PR-Cryo FC D10

ExTEM CT (sec)

86.0 (78.5–104.3)

59.0 (48.5–69.5)

86.5 (73.5–102.0)

72.5 (70.8–79.5)

ExTEM CFT (sec)

122.0 (107.0–134.5)

189 (124.5–227.5)

102.5 (90.8–110.8)

107.5 (89.0–123.0)

ExTEM MCF (mm)

52.0 (51.0–54.3)

45.5 (43.5–50.3)

54.0 (52.3–56.3)

54.0 (52.3–55.0)

p values

dWB
‡‡,#,$
‡‡,$
‡‡,$$

ExTEM LY60 (%)

2.5 (1.8–3.5)

5.0 (3.3–6.8)

5.5 (2.5–7.3)

2.5 (0.8–5.0)

TG ETP (nM*min)

964.4 (532.6–1166)

1601 (1414–1753)

1947 (1754–2162)

1720 (1521–1883)

TG Lagtime (min)

7.09 (6.83–7.67)

4.67 (3.13–5.92)

6.59 (5.88–7.42)

8.75 (7.08–9.17)

TG Peak (nM)

37.2 (19.0–44.6)

132.9 (109.6–154.6)

129.5 (93.2–153.2)

99.4 (68.6–135.9)

**,##

TG ttPeak (min)

19.7 (18.6–20.9)

8.7 (5.7–12.1)

12.3 (9.6–15.1)

15.5 (11.6–18.4)

**,$

FGN (mg/dl)

273.0 (250.8–284.3)

204.5 (184.8–273.5)

235.0 (217.8–240.3)

206.0 (193.8–213.0)

**,##,¶

FVIII (%)

19.0 (14.5–24.0)

71.00 (56.3–82.3)

64.0 (56.0–68.5)

52.0 (45.8–79.8)

**,##

FXIII (%)

50.5 (44.5–56.5)

104.5 (70.3–123.5)

95.0 (89.0–126.5)

88.5 (82.3–139.8)

**,##

VWF (%)

42.5 (38.8–47.5)

94.0 (81.3–152.8)

123.5 (103.3–137.0)

126.0 (106.3–148.0)

**,##

ExTEM CT (sec)

68.0 (61.8–79.0)

54.5 (43.3–77.3)

71.0 (65.8–83.5)

77.0 (61.3–86.8)

ExTEM CFT (sec)

69.0 (62.3–75.8)

88.5 (69.0–129.0)

59.5 (55.5–71.3)

69.5 (65.8–96.0)

ExTEM MCF (mm)

64.0 (62.0–68.0)

62.0 (57.3–65.5)

69.0 (66.8–70.0)

64.5 (61.5–67.3)

ExTEM LY60 (%)

7.5 (5.8–28.8)

11.0 (5.5–15.0)

7.5 (5.0–11.0)

5.5 (4.5–11.0)

TG ETP (nM*min)

1906 (1783–2333)

1671 (1401–1842)

2267 (1775–2528)

1841 (1674–2137)

TG Lagtime (min)

5.84 (5.46–6.54)

4.50 (3.46–5.33)

5.59 (4.92–6.75)

7.34 (6.42–7.96)

$$

TG Peak (nM)

114.8 (87.6–152.1)

255.3 (174.4–357.6)

272.0 (148.1–380.7)

199.8 (116.7–304.8)

**

TG ttPeak (min)

12.3 (11.5–16.7)

7.7 (5.8–9.8)

9.4 (7.6–11.4)

12.1 (9.4–14.4)

$

FGN (mg/dl)

525.5 (498.8–559.3)

401.5 (374.8–542.3)

497.0 (456.0–529.8)

420.0 (399.0–458.5)

#

FVIII (%)

55.0 (52.5–79.8)

124.5 (113.0–152.8)

107.5 (83.0–146.3)

100.5 (85.3–159.3)

*,#

FXIII (%)

137.5 (127.3–153.3)

197.5 (150.3–211.5)

208.0 (173.8–237.5)

201.0 (165.3–254.3)

**,##

VWF (%)

103.0 (97.0–115.5)

165.0 (149.5–264.5)

212.5 (191.5–242.5)

228.0 (207.0–297.3)

**,##

**,‡,##
‡,$$

lyWB
‡
‡‡,¶

‡

Note: Values reported as median (interquartile range [IQR; Quartile 1–Quartile 3]). Mann–Whitney tests comparing rank sums for comparing FibCon to D5
PR-Cryo FC (*p < .05; **p < .01), FibCon to D10 PR-Cryo FC (#p < .05; ##p < .01), D0 Cryo to D5 PR-Cryo FC (‡p < .05; ‡‡p < .01), D0 Cryo to D10 PR-Cryo FC
($p < .05; $$p < .01), or D5 PR-Cryo FC to D10 PR-Cryo FC (¶p < .05).

between D5 and D10 PR-Cryo FC in rescue of both
coagulopathies. FGN levels were slightly elevated in D5
PR-Cryo FC:dWB compared to D10 PR-Cryo FC:dWB,
and while the difference in MCF between D5 PR-Cryo
FC:lyWB and D10 PR-Cryo FC:lyWB was significant, the
absolute difference was only 2.5 mm and both MCF
values remained above 60 mm.
To identify if hemostatic adjunct type correlated with
any particular hemostatic profile of rescued
coagulopathies, we performed Pearson's correlations for
all reported parameters and adjuncts on D0 in both
dilutional (Figure 4(A)) and lytic coagulopathies
(Figure 4(B)). We found the variable “adjunct” was
strongly and significantly correlated to factor levels and
thrombin generation in dilutional coagulopathy rescue
(Figure 4(A), (C)) but not as strongly in lytic

coagulopathy rescue (Figure 4(B),(D)). Specifically, CT,
lag time, and time to peak thrombin generation all positively and significantly correlated with study product in
the dilutional coagulopathy (Figure 4(A),(C)), but less so
in the lytic coagulopathy (Figure 4(B),(D)). Factor levels
were more significantly associated with thrombin generation in the dilutional coagulopathy (dark pink lower right
quadrant, Figure 4(C)) compared to the lytic coagulopathy
(Figure 4(D)).

4 | DISCUSSION
This study is unique in a few ways: (i) the hemostatic efficacy of PR-Cryo FC was compared to both Cryo and
FibCon within the same set of experiments;
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F I G U R E 4 Correlation of hemostatic parameters in adjunct rescued coagulopathies. Parameters: adjunct (PR-Cryo FC D0, Cryo D0, and
FibCon D0), clotting time (CT, seconds), clot formation time (CFT, seconds), maximal clot firmness (MCF, mm), percent lysis at 60 min
(LY60, %), endogenous thrombin potential (ETP, nM*min), fibrinogen (FGN, mg/dl), factor VIII (FVIII, %), factor XIII (FXIII, %), and von
Willebrand factor (VWF). (A) Matrix of Pearson's correlation coefficients (−1.0 to 1.0) between given parameters in dilutional coagulopathies
rescued by D0 adjuncts. (B) Matrix of Pearson's correlation coefficients (−1.0 to 1.0) between given parameters in lytic coagulopathies
rescued by D0 adjuncts. (C) Matrix of p-values (0.0–0.05) associated with Pearson's correlation coefficients between given parameters in
dilutional coagulopathies rescued by D0 adjuncts. White squares represent nonsignificant Pearson's correlations. (D) Matrix of p-values
(0.0–0.05) associated with Pearson's correlation coefficients between given parameters in lytic coagulopathies rescued by D0 adjuncts. White
squares represent nonsignificant Pearson's correlations

(ii) cryoprecipitate products were analyzed out to 10 days
of storage at room temperature; (iii) we measured PRCryo FC efficacy in rescuing in vitro induced lytic and
dilutional coagulopathies; and (iv) we incorporated the
use of thrombin generation capacity as a functional measure of hemostasis for both dilutional and lytic
coagulopathies. Our results indicate as expected that PRCryo FC and Cryo provided more VWF, FVIII, and FXIII
upon mixture with dilutional or lytic coagulopathies
compared to FibCon. This was maintained throughout
storage as D10 PR-Cryo FC dilutional and lytic
coagulopathic mixtures had significantly increased levels
of VWF, FVIII, and FXIII compared to FibCon:dWB or
FibCon:lyWB coagulopathic mixtures, but not Cryo:dWB
or Cryo:lyWB coagulopathic mixtures. Notably, the

dilutional coagulopathy provided an optimal platform to
assess the hemostatic function of study products compared to the lytic coagulopathy due to the inherently
lower concentrations of coagulation factors in salinediluted WB. This was recapitulated in our correlation
analyses, which revealed significant relationships
between factor levels and thrombin generation in
dilutional but not lytic coagulopathies. These data highlight that in settings where multiple factors may need to
be restored, such as dilutional coagulopathy, that
cryoprecipitate-based products may serve as a better
hemostatic adjunct than fibrinogen concentrates.
Our data show that the additional FXIII available in
cryoprecipitate products did not greatly improve hemostatic rescue in the lytic coagulopathy. The lytic model
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was created to target 10%–15% lysis (via ROTEM) using
exogenous tPA; the quantity of FXIII in the
cryoprecipitate products may not have been enough to
overcome the effects of 75 ng/ml tPA. Future studies
evaluating cryoprecipitate product dosage in conjunction
with various tPA concentrations may identify a key range
of lysis where standard cryoprecipitate dosing would be
beneficial.
This study is the first to measure thrombin generation
induced by PR-Cryo FC rescue of WB-based
coagulopathy models, as Kamyszek et al. demonstrated
the intrinsic ability of PR-Cryo FC to promote thrombin
generation (adjunct alone).29 We found thrombin generation was greater when PR-Cryo FC or Cryo were mixed
into dilutional coagulopathy, compared to FibCon,
irrespective of storage duration. However, this difference
was not apparent in study product:lytic coagulopathic
mixtures. In both coagulopathies, there were no differences in thrombin generation between PR-Cryo FC and
Cryo, suggesting both products support similar hemostatic capacity with respect to thrombin generation.
These data support the theory that cryoprecipitate products provide a more efficacious hemostatic resuscitation
than fibrinogen concentrates alone via the ability to promote thrombin generation.19,23
Both PR-Cryo FC:dWB and Cryo:dWB had reduced
time to initial fibrin formation (CT) compared to
FibCon:dWB, reaffirming that additional factors available in Cryo products are important for clot initiation.28
There were no significant differences between additional ROTEM variables in PR-Cryo FC and Cryo
dilutional coagulopathic mixtures, suggesting that PR
has minimal effect on clot formation, as seen before.28
These data demonstrate that supplementation with factors upstream of fibrinogen will increase the kinetics of
clot formation, but if FGN concentration is similar
between adjuncts, then terminal clot formation will be
relatively equivalent.
Our study was designed in a reductionist manner to
understand the relative contributions of each adjunct to
both dilutional and lytic coagulopathies. Hemostatic
adjuncts are rarely transfused alone when treating
hemorrhaging patients; as such, future work assessing
hemostatic adjunct efficacy in combination with other
transfused products such as packed red blood cells and/or
platelets will help to inform on the efficacy of hemostatic
adjuncts. Specifically, our data demonstrating enhanced
thrombin
generation
upon
resuscitation
with
cryoprecipitate products suggest a potential for additional
augmented thrombin generation. This may be beneficial
for patients who have a dilutional or consumptive
coagulopathy where the concentration of thrombin is
potentially lower than required for hemostasis. In

THOMAS ET AL.

addition, we used PRP derived from adjunct-resuscitated
coagulopathies to measure the maximal ETP upon
resuscitation—to include adjunct interaction with platelets. To measure the thrombin potential associated with
adjuncts alone in absence of platelets, one would need to
measure thrombin generation in PPP derived from the
adjunct-resuscitated coagulopathies. Our study did not
assess hemostatic rescue by PR-Cryo FC, Cryo, and
FibCon under physiologically relevant flow conditions.
Flow regimes are a significant component of clot formation in vivo32; therefore, future studies of hemostatic
adjunct efficacy should incorporate flow, such as the use
of microfluidic models of bleeding. Logistical constraints
of our study (product storage times, WB volumes
required, and assay/workflow throughput) limited the
number of each product tested (n = 6 for each group)
and hindered us from using the same WB donors for the
duration of each storage period, leading to large amounts
of variability in data generated from resuscitated samples.
Lastly and unfortunately, there is a lack of established
relevance of these in vitro functions in context of patient
outcomes. How differences we identify here can be
extrapolated in vivo in actively bleeding patients with
complex coagulopathies remains to be determined.
Providing fibrinogen to traumatically bleeding
patients is clearly beneficial, yet it is important to recognize that fibrinogen supplementation alone may not
be effective if upstream pathways regulating fibrinogen
use are also dysregulated due to trauma-associated
coagulopathies.
Our
results
demonstrate
that
cryoprecipitate products provide an advantage with
respect to reducing the time to clot formation compared to fibrinogen concentrates and may be more
helpful in cases of iatrogenic dilutional coagulopathy.
Moreover, PR-Cryo FC is hemostatically stable over
10 days of storage at 20–24°C, and D10-stored PR-Cryo
FC provides similar hemostatic function compared to
FibCon. The ability to increase the post-thaw storage
duration to 10 days at room temperature without risk
of bacterial growth would allow for PR-Cryo FC products to be immediately available for use and provide a
product that may be superior for patients with a
dilutional coagulopathy. This has great potential to
improve outcomes in patients with severe traumatic
bleeding as immediate access to a hemostatic agent is
essential for resuscitation, and every single minute
delay in providing any blood product to a severely
bleeding trauma patient increases mortality by 5%.33
As FibCon reconstitution time is approximately
15 min, the immediate availability and use of PR-Cryo
FC or Cryo products could have a significant effect on
outcomes in traumatically injured patients with severe
bleeding.
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